MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
+$0.08 today
- Market cap
- $125.90M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
Volume 0.72M
Average 0.98M
MGNX Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
MacroGenics, Inc.NASDAQ: MGNX
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital dips below year-ago levels
Q1 FY2026 change in working capital of $1.77M (cash outflow) fell 85.5% year over year, behind the +67.2% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at +66.6% a year.
Context
- Change in working capital amounted to 19.0% of revenue in FY2025, up 18.0 pp from a year earlier.
- Change in working capital increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -85.5% toward the trailing-twelve-month pace of +67.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (28.33M) USD
- Year-over-year change
- -2135.3%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (28.33M) | -2135.3% |
| FY2024 | 2024-12-31 | 1.39M | -97.4% |
| FY2023 | 2023-12-31 | 53.32M | +969.8% |
| FY2022 | 2022-12-31 | (6.13M) | -134.9% |
| FY2021 | 2021-12-31 | 17.57M | — |
Change in Working Capital vs competitors
How MGNX compares with its peers on the latest reported figures
- Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +67.2% is the 5th highest of 11, against a peer median of -49.4%.
- Change in working capital amounts to 11.4% of revenue for MGNX, versus a peer median of 172.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $17.87M USD | +67.2% | +66.6% | 11.4% | |
| LTM Mar 2026 | $15.66M USD | +595.3% | +26.5% | — | |
| LTM Mar 2026 | $11.6M USD | -384.3% | — | — | |
| LTM Mar 2026 | €8.45M EUR | +450.5% | — | 28812.5% | |
| LTM Mar 2026 | $4.28M USD | -7474.4% | +29.6% | 3191.9% | |
| LTM Mar 2026 | $3.86M USD | +216.5% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $1.93M USD | -48.2% | — | 27.0% |
| LTM Mar 2026 | $1.73M USD | -162.8% | -44.0% | 172.9% | |
| LTM Mar 2026 | $721.9K USD | -50.6% | +72.8% | 9.1% | |
| FY2025 | $580K USD | +103.7% | -56.7% | 906.3% | |
| LTM Mar 2026 | $469K USD | -263.4% | -20.7% | 6.6% | |
| Peer median (excluding MGNX) | — | -49.4% | +2.9% | 172.9% | |
Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (202.12M) | (119.76M) | (9.06M) | (66.97M) | (74.62M) |
| Depreciation & Amortization | 11.26M | 11.87M | 9.65M | 7.54M | 5.52M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.13M | 20.44M | 18.37M | 29.44M | 14.29M |
| Change in Working Capital | 17.57M | (6.13M) | 53.32M | 1.39M | (28.33M) |
| Accounts Receivables | 12.7M | (45.84M) | 45.86M | 6.06M | (9.06M) |
| Inventory | (6.42M) | 55K | 230K | (2.19M) | (7.91M) |
| Accounts Payables | 7.13M | (10.86M) | 1.28M | (1.53M) | (280K) |
| Other Working Capital | 4.17M | 50.51M | 5.95M | (948K) | (11.08M) |
| Other Non-Cash Items | 6.33M | 6.63M | (150.48M) | (39.78M) | 2.1M |
| Operating Cash Flow | (143.83M) | (86.96M) | (78.21M) | (68.37M) | (81.04M) |
| Capital Expenditures | (6.2M) | (3.62M) | (1.76M) | (3.71M) | (1.91M) |
| Acquisitions (Net) | 0 | 0 | 64K | 0 | 11K |
| Purchases of Investments | (231.21M) | (120.6M) | (239.68M) | (77.18M) | (208.34M) |
| Sales of Investments | 200.8M | 194.94M | 161.3M | 190.03M | 96.14M |
| Other Investing Activities | 0 | 0 | 0 | 40.16M | 0 |
| Investing Cash Flow | (36.61M) | 70.72M | (80.08M) | 149.3M | (114.1M) |
| Debt Repayment | 0 | 0 | (157K) | 0 | 0 |
| Common Stock Issued | 117.82M | 1.09M | 1.17M | 3.44M | 129K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.96M | 574K | 149.35M | 960K | 69.39M |
| Financing Cash Flow | 122.78M | 1.66M | 150.36M | 960K | 69.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (57.66M) | (14.59M) | (7.93M) | 81.88M | (125.62M) |
| Free Cash Flow | (150.03M) | (90.58M) | (79.97M) | (72.08M) | (82.95M) |
MacroGenics, Inc.
NASDAQ:MGNX
Intrinsic Alpha fair value
Locked
Current Price
$1.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.